Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Propanc Biopharma Inc
(OP:
PPCB
)
0.0003
UNCHANGED
Streaming Delayed Price
Updated: 3:41 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Propanc Biopharma Inc
< Previous
1
2
Next >
Propanc Biopharma’s Peer Reviewed Articles for Proenzymes Cancer Treatment Generates “Unprecedented” Interest
August 21, 2024
From
Propanc Biopharma, Inc.
Via
Business Wire
Propanc Biopharma Receives Notice of Allowance for “Proenzyme Composition” Patent in North America
August 14, 2024
From
Propanc Biopharma, Inc.
Via
Business Wire
Propanc Biopharma’s CSO Predicts PRP Could Solve Problem That Impacts Response Rate of Immune Checkpoint Inhibitors Treating Solid Tumors
July 17, 2024
From
Propanc Biopharma, Inc.
Via
Business Wire
Propanc Biopharma Receives Certificate of Grant for “Proenzymes Composition” Patent from Japanese Patent Office
June 25, 2024
From
Propanc Biopharma, Inc.
Via
Business Wire
Propanc Biopharma Receives Certificate of Grant for “Composition of Proenzymes for Cancer Treatment” Patent from European Patent Office
April 16, 2024
From
Propanc Biopharma, Inc.
Via
Business Wire
Propanc Biopharma’s CEO Shares Views on Revolutionizing Cancer Treatment: An Inside Look at Drug Development & Strategic Financing
April 08, 2024
From
Propanc Biopharma
Via
Business Wire
Propanc Biopharma to Host Corporate Update Call Highlighting Recent Progress and Positive Results from Compassionate Use Study
February 22, 2024
From
Propanc Biopharma, Inc
Via
Business Wire
Propanc Biopharma Receives Certificate of Grant for PRP Foundation Patent from Canadian Intellectual Property Office
January 16, 2024
From
Propanc Biopharma, Inc.
Via
Business Wire
Propanc Biopharma Engages Boutique Advisory Firm to Identify Strategic Investment Opportunities
December 18, 2023
From
Propanc Biopharma, Inc.
Via
Business Wire
Propanc Biopharma’s Joint Research Partner Pushing Boundaries to Circumvent Chemotherapy Resistance Using PRP
December 13, 2023
From
Propanc Biopharma, Inc.
Via
Business Wire
Propanc Biopharma Confirms PRP Enhances Chemosensitivity and Alters Tumor Microenvironment of Pancreatic Tumor Cells
November 07, 2023
From
Propanc Biopharma, Inc.
Via
Business Wire
Propanc Biopharma Targets Site of First-In-Human Study for PRP at the Peter Mac Cancer Center, Melbourne, Australia
August 15, 2023
From
Propanc Biopharma, Inc.
Via
Business Wire
Propanc Biopharma’s Clinical Candidate PRP Targeting Pancreatic Cancer Market Forecast to Reach $6.93 Billion by 2030
July 25, 2023
From
Propanc Biopharma, Inc.
Via
Business Wire
Propanc Biopharma Peer Reviewed Scientific Article Reaches 3,000 Reads
July 13, 2023
From
Propanc Biopharma, Inc.
Via
Business Wire
Propanc Biopharma Produces Synthetic Recombinant Proenzymes for Cancer Therapy Targeting Advanced Solid Tumors
July 05, 2023
From
Propanc Biopharma, Inc.
Via
Business Wire
Propanc Biopharma Provides Shareholder Update
June 22, 2023
From
Propanc Biopharma, Inc.
Via
Business Wire
Propanc Biopharma’s Intellectual Property Portfolio Achieves Significant Milestones in North America
May 23, 2023
From
Propanc Biopharma, Inc.
Via
Business Wire
Propanc Biopharma Announces Reverse Stock Split
May 22, 2023
From
Propanc Biopharma, Inc.
Via
Business Wire
Propanc Biopharma Announces That PRP Suppresses TGF-β Pathway & Tumor Microenvironment in Pancreatic Cancer
March 28, 2023
From
Propanc Biopharma, Inc.
Via
Business Wire
Propanc Biopharma Confirms PRP Exerts Significant Effects Against Chemoresistant Pancreatic Tumor Cells
March 16, 2023
From
Propanc Biopharma, Inc.
Via
Business Wire
Propanc Biopharma’s Joint Researcher Presents at the 43rd Meeting of the European Organization of Research & Treatment of Cancer (EORTC)
January 11, 2023
From
Propanc Biopharma, Inc.
Via
Business Wire
Propanc Biopharma’s Joint Researcher Receives Award at Doctoral Conference at the University of Jaén
December 15, 2022
From
Propanc Biopharma, Inc.
Via
Business Wire
Propanc Biopharma Concludes PRP Could Become an Effective Chemosensitizer Agent Against Pancreatic Cancer
November 30, 2022
From
Propanc Biopharma, Inc.
Via
Business Wire
Propanc Biopharma’s CSO Predicts PRP Could Enhance Therapeutic Effects of Immune Checkpoint Therapy for Pancreatic Cancer
November 15, 2022
From
Propanc Biopharma, Inc.
Via
Business Wire
Propanc Biopharma, Inc. (PPCB) Featured in Virtual Coverage of the Sidoti & Company Micro-Cap Investor Conference
November 04, 2022
Via
Investor Brand Network
Propanc Biopharma’s CEO to Present at Sidoti & Company Micro-Cap Virtual Investor Conference
October 26, 2022
From
Propanc Biopharma, Inc.
Via
Business Wire
Propanc Biopharma’s CEO to Attend 43rd Meeting of the European Organization of Research & Treatment of Cancer (EORTC), Dec 15 - 17
October 12, 2022
From
Propanc Biopharma, Inc.
Via
Business Wire
Propanc Biopharma Targets Pancreatic & Ovarian Cancers for PRP Clinical Studies with Combined Markets to Reach Over $14.3 Billion by 2027
September 29, 2022
From
Propanc Biopharma, Inc.
Via
Business Wire
Propanc Biopharma Provides Shareholder Update
September 13, 2022
From
Propanc Biopharma, Inc.
Via
Business Wire
Propanc Biopharma Reports Significant Effects of PRP Against the Tumor Microenvironment
September 08, 2022
From
Propanc Biopharma, Inc.
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.